PL3129483T3 - Terapia skojarzona do leczenia chorób autoimmunologicznych - Google Patents

Terapia skojarzona do leczenia chorób autoimmunologicznych

Info

Publication number
PL3129483T3
PL3129483T3 PL14716560T PL14716560T PL3129483T3 PL 3129483 T3 PL3129483 T3 PL 3129483T3 PL 14716560 T PL14716560 T PL 14716560T PL 14716560 T PL14716560 T PL 14716560T PL 3129483 T3 PL3129483 T3 PL 3129483T3
Authority
PL
Poland
Prior art keywords
treatment
combination therapy
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
PL14716560T
Other languages
English (en)
Inventor
Urs Christen
Stanley LASCH
Michael Parnham
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Publication of PL3129483T3 publication Critical patent/PL3129483T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14716560T 2014-04-08 2014-04-08 Terapia skojarzona do leczenia chorób autoimmunologicznych PL3129483T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2014/057077 WO2015154795A1 (en) 2014-04-08 2014-04-08 Combination therapy for the treatment of autoimmune diseases
EP14716560.9A EP3129483B1 (en) 2014-04-08 2014-04-08 Combination therapy for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
PL3129483T3 true PL3129483T3 (pl) 2019-05-31

Family

ID=50478392

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14716560T PL3129483T3 (pl) 2014-04-08 2014-04-08 Terapia skojarzona do leczenia chorób autoimmunologicznych

Country Status (9)

Country Link
US (3) US10413605B2 (pl)
EP (1) EP3129483B1 (pl)
JP (1) JP6485970B2 (pl)
KR (1) KR102459720B1 (pl)
CN (1) CN106459971B (pl)
CA (1) CA2944811C (pl)
ES (1) ES2717661T3 (pl)
PL (1) PL3129483T3 (pl)
WO (1) WO2015154795A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129483B1 (en) * 2014-04-08 2018-11-21 Fraunhofer Gesellschaft zur Förderung der Angewand Combination therapy for the treatment of autoimmune diseases
PE20191404A1 (es) 2017-01-27 2019-10-04 Ngm Biopharmaceuticals Inc Proteinas de union al receptor de glucagon y metodos para usarlas
US20210048429A1 (en) * 2017-10-23 2021-02-18 Vipin Kumar Chaturvedi Plzf+ regulatory cd8 t cells for control of inflammation
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CA3267179A1 (en) 2022-09-09 2024-03-14 Idorsia Pharmaceuticals Ltd PHARMACEUTICAL COMBINATION INCLUDING AN ANTI-CD3 ANTIBODY AND A CXCR3 ANTAGONIST

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120263733A1 (en) 2002-11-15 2012-10-18 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
EP1902320B1 (en) * 2005-05-20 2010-03-10 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
CA2614640A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
WO2012098238A1 (en) 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
CN104870013A (zh) 2012-06-27 2015-08-26 吉安特科技公司 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
EP3129483B1 (en) * 2014-04-08 2018-11-21 Fraunhofer Gesellschaft zur Förderung der Angewand Combination therapy for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
US20190351056A1 (en) 2019-11-21
ES2717661T3 (es) 2019-06-24
US20220257755A1 (en) 2022-08-18
CN106459971A (zh) 2017-02-22
CA2944811A1 (en) 2015-10-15
US20170021018A1 (en) 2017-01-26
CA2944811C (en) 2022-06-21
EP3129483A1 (en) 2017-02-15
KR102459720B1 (ko) 2022-10-26
EP3129483B1 (en) 2018-11-21
JP6485970B2 (ja) 2019-03-20
KR20160133479A (ko) 2016-11-22
CN106459971B (zh) 2019-08-16
JP2017510594A (ja) 2017-04-13
WO2015154795A1 (en) 2015-10-15
US10413605B2 (en) 2019-09-17

Similar Documents

Publication Publication Date Title
PT3212233T (pt) Terapia combinada para o tratamento de doenças
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
SMT201900176T1 (it) Terapia con mrna per il trattamento di malattie oculari
SG11201609770TA (en) Combination therapies for the treatment of cancer
IL250059B (en) Altered 2-il variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
IL256224B (en) Combined therapy for cancer treatment
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
IL258521A (en) Combination of treatments for cancer treatment
SI3122358T1 (sl) Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
IL250990A0 (en) Materials for human care
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
GB201412578D0 (en) Treatment of neurological diseases
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
GB201414023D0 (en) Treatment of autoimmune diseases
GB201514909D0 (en) Treatment of autoimmune diseases
GB201506944D0 (en) Therapeutic treatment
PT3546585T (pt) Ácidos nucleicos compreendendo um intrão modificado para utilização no tratamento de hiperbilirrubinemia
AU2014902075A0 (en) New Therapeutic Treatment Combination
GB201413533D0 (en) Combination therapy for treating disorders of the vestibular system
GB201412285D0 (en) Therapeutic treatments
GB201412293D0 (en) Therapeutic treatments